View Older Stories View More Recent Stories

Jul 18, 2023 05:00PM First Patient Dosed in STARSTRUCK Study of TLX250 Targeted Radiation Therapy in Combination with Merck Investigational DNA-PK Inhibitor, Peposertib
Jun 26, 2023 03:50PM New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC
Jun 22, 2023 07:00AM Telix to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI
Jun 21, 2023 05:24AM Telix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint Medical
Jun 20, 2023 06:29PM Telix Urology Innovation Showcase to be held at The Yale Club, New York City
Jun 18, 2023 08:09PM First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion
Jun 15, 2023 07:00AM Telix Briefing: Innovation in Urology to Feature Key Opinion Leaders in Prostate and Kidney Cancer
Jun 8, 2023 08:00AM Telix Opens European Radiopharmaceutical Production Facility
Jun 5, 2023 08:39PM Telix to Present at Jefferies Healthcare Conference
May 25, 2023 07:00AM Telix to Host Briefing with U.S. Leadership Team and Key Opinion Leaders to Highlight Innovation in Urology
May 7, 2023 05:00PM Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study
May 1, 2023 01:00PM First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide
Apr 30, 2023 08:47PM ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller
Apr 26, 2023 06:45PM Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid
Apr 17, 2023 06:04AM Telix Reports Q1 2023 Financial Results: Delivers First $100M Revenue Quarter
Apr 16, 2023 06:35PM Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical
Mar 16, 2023 08:28AM FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy
Feb 27, 2023 01:24AM Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive
Feb 19, 2023 04:27PM Detailed Results from Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU
Feb 14, 2023 03:49PM Telix Collaboration on Next Generation Urologic-Oncology Theranostic Published in Journal of Nuclear Medicine
Jan 8, 2023 05:01PM Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update
Dec 21, 2022 05:02PM ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances
Dec 4, 2022 05:38PM Telix Announces Executive Leadership Appointments
Nov 22, 2022 07:00AM Illuccix® Available on High Activity Gallium Generator Technology to Meet High Demand
Nov 21, 2022 03:56PM First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy
Nov 13, 2022 04:54PM Telix Acquires Optimal Tracers
Nov 11, 2022 07:00AM Telix to Present at Jefferies London Healthcare Conference 2022
Nov 6, 2022 05:44PM Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study
Oct 19, 2022 06:06PM Telix Reports Third Quarter 2022 Financial Results
Oct 17, 2022 01:00AM Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market
Oct 16, 2022 05:43PM Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging
Oct 13, 2022 08:13PM Health Canada Approves Illuccix® for Prostate Cancer Imaging
Sep 27, 2022 06:49PM Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate
Sep 26, 2022 05:00PM First Patient Enrolled in ProstACT TARGET Study
Sep 20, 2022 07:29PM Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data
Aug 1, 2022 06:51PM Telix APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging
Jul 27, 2022 08:30AM BAMF Health and Telix complete first total-body PET scans with Illuccix for prostate cancer imaging
Jul 20, 2022 08:27PM Telix Reports Second Quarter 2022 Financial Results
Jul 10, 2022 07:02PM ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment
Jul 10, 2022 06:57PM Kevin Richardson appointed as CEO, Telix Americas
Jun 14, 2022 07:00AM Telix and Invicro Advance AI Partnership
Jun 13, 2022 07:11AM Jubilant Radiopharma Joins Illuccix® Pharmacy Partner Network
Jun 10, 2022 07:00AM Telix and RefleXion Expand Partnership for Prostate Cancer Treatment
Jun 7, 2022 07:00AM Telix to Present at Jefferies Healthcare Conference
Jun 6, 2022 07:00AM Telix Showcasing Innovation in Theranostics at SNMMI
May 31, 2022 07:00AM Illuccix® Granted Transitional Pass-Through Payment Status
May 10, 2022 12:00AM Monrol Is Partnering With Telix Pharmaceuticals, Supplying Lutetium nca Lu 177 for the Manufacturing of Clinical Doses for the Phase II STARLITE 2 Study At MSK and Manufacturing Clinical Doses for Tel
May 4, 2022 05:00PM First Patient Dosed in Phase II Renal Cancer Theranostics Study
Apr 14, 2022 07:00AM First Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent
Apr 11, 2022 07:42PM ProstACT Update: TARGET Study Ethics Approval
View More Recent Stories View Older Stories